RNAi疗法lumasiran获得欧盟批准治疗1型原发性高草酸尿症

2020-11-20 MedSci原创 MedSci原创

Alnylam Pharmaceuticals宣布,欧盟委员会批准了其RNAi治疗药物Oxlumo(lumasiran)用于治疗1型原发性高草酸尿症(PH1)。

Alnylam Pharmaceuticals宣布,欧盟委员会批准了其RNAi治疗药物Oxlumo(lumasiran)用于治疗1型原发性高草酸尿症(PH1)。Lumasiran通过降解HAO1 mRNA和消耗乙醇酸氧化酶来发挥作用,乙醇酸氧化酶则进一步抑制肝脏过度生产的草酸盐,草酸盐可促进PH1疾病进展。

图片来源:seekingalpha.com

首席执行官John Maraganore表示:“ Alnylam的Lumasiran从发现到获得监管机构批准仅仅花了六年时间。” 上个月,欧洲药品管理局人用药品委员会基于两项III期试验的数据发表了正面意见,此后获得了监管部门的批准。

在ILLUMINATE-A中,包括成人和六岁及以上的儿童Oxlumo达到了主要终点,尿草酸盐相对于安慰剂平均减少了53.5%,并且草酸盐相对于基线平均减少了65.4%。与安慰剂组相比,大多数接受Oxlumo治疗患者的草酸尿水平也达到了正常或接近正常水平。同时,在六岁以下婴幼儿中评估的ILLUMINATE-B研究也显示Oxlumo的疗效结果和安全性与ILLUMINATE-A中观察到的相当。

图片来源:seekingalpha.com

该疗法是由医护人员每月一次皮下注射,持续三个月,然后每季度一次。Oxlumo也在美国被授予优先审查,FDA预计将于12月3日做出决定。

原始出处:

https://www.firstwordpharma.com/node/1775889?tsid=28&region_id=2

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1846941, encodeId=15ab18469417a, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Jun 07 08:41:49 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751687, encodeId=8b631e5168768, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Sun Jan 24 00:41:49 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901503, encodeId=8f75901503d7, content=替代移植吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/5A52F5B6BEDC82694F39CB1D2A5D1CF1/100, createdBy=2a7c2136456, createdName=chenwb091, createdTime=Mon Nov 23 17:22:21 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536872, encodeId=44a715368e287, content=<a href='/topic/show?id=7cad1554076' target=_blank style='color:#2F92EE;'>#RNAi疗法Lumasiran#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15540, encryptionId=7cad1554076, topicName=RNAi疗法Lumasiran)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1712732896, createdName=fzwish20004, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590036, encodeId=744e159003607, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900810, encodeId=dec3900810f5, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>lumasiran获得<a href='/topic/show?id=135a63113db' target=_blank style='color:#2F92EE;'>#欧盟#</a>批准治疗1型<a href='/topic/show?id=92f13e13717' target=_blank style='color:#2F92EE;'>#原发性高草酸尿症#</a>,RNAi疗法的新药很快就会大量问世了, beContent=null, objectType=article, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=63113, encryptionId=135a63113db, topicName=欧盟), TopicDto(id=37137, encryptionId=92f13e13717, topicName=原发性高草酸尿症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:41:26 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1846941, encodeId=15ab18469417a, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Jun 07 08:41:49 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751687, encodeId=8b631e5168768, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Sun Jan 24 00:41:49 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901503, encodeId=8f75901503d7, content=替代移植吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/5A52F5B6BEDC82694F39CB1D2A5D1CF1/100, createdBy=2a7c2136456, createdName=chenwb091, createdTime=Mon Nov 23 17:22:21 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536872, encodeId=44a715368e287, content=<a href='/topic/show?id=7cad1554076' target=_blank style='color:#2F92EE;'>#RNAi疗法Lumasiran#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15540, encryptionId=7cad1554076, topicName=RNAi疗法Lumasiran)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1712732896, createdName=fzwish20004, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590036, encodeId=744e159003607, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900810, encodeId=dec3900810f5, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>lumasiran获得<a href='/topic/show?id=135a63113db' target=_blank style='color:#2F92EE;'>#欧盟#</a>批准治疗1型<a href='/topic/show?id=92f13e13717' target=_blank style='color:#2F92EE;'>#原发性高草酸尿症#</a>,RNAi疗法的新药很快就会大量问世了, beContent=null, objectType=article, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=63113, encryptionId=135a63113db, topicName=欧盟), TopicDto(id=37137, encryptionId=92f13e13717, topicName=原发性高草酸尿症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:41:26 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
    2021-01-24 yinxm8315
  3. [GetPortalCommentsPageByObjectIdResponse(id=1846941, encodeId=15ab18469417a, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Jun 07 08:41:49 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751687, encodeId=8b631e5168768, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Sun Jan 24 00:41:49 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901503, encodeId=8f75901503d7, content=替代移植吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/5A52F5B6BEDC82694F39CB1D2A5D1CF1/100, createdBy=2a7c2136456, createdName=chenwb091, createdTime=Mon Nov 23 17:22:21 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536872, encodeId=44a715368e287, content=<a href='/topic/show?id=7cad1554076' target=_blank style='color:#2F92EE;'>#RNAi疗法Lumasiran#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15540, encryptionId=7cad1554076, topicName=RNAi疗法Lumasiran)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1712732896, createdName=fzwish20004, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590036, encodeId=744e159003607, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900810, encodeId=dec3900810f5, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>lumasiran获得<a href='/topic/show?id=135a63113db' target=_blank style='color:#2F92EE;'>#欧盟#</a>批准治疗1型<a href='/topic/show?id=92f13e13717' target=_blank style='color:#2F92EE;'>#原发性高草酸尿症#</a>,RNAi疗法的新药很快就会大量问世了, beContent=null, objectType=article, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=63113, encryptionId=135a63113db, topicName=欧盟), TopicDto(id=37137, encryptionId=92f13e13717, topicName=原发性高草酸尿症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:41:26 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
    2020-11-23 chenwb091

    替代移植吗

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1846941, encodeId=15ab18469417a, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Jun 07 08:41:49 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751687, encodeId=8b631e5168768, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Sun Jan 24 00:41:49 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901503, encodeId=8f75901503d7, content=替代移植吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/5A52F5B6BEDC82694F39CB1D2A5D1CF1/100, createdBy=2a7c2136456, createdName=chenwb091, createdTime=Mon Nov 23 17:22:21 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536872, encodeId=44a715368e287, content=<a href='/topic/show?id=7cad1554076' target=_blank style='color:#2F92EE;'>#RNAi疗法Lumasiran#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15540, encryptionId=7cad1554076, topicName=RNAi疗法Lumasiran)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1712732896, createdName=fzwish20004, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590036, encodeId=744e159003607, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900810, encodeId=dec3900810f5, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>lumasiran获得<a href='/topic/show?id=135a63113db' target=_blank style='color:#2F92EE;'>#欧盟#</a>批准治疗1型<a href='/topic/show?id=92f13e13717' target=_blank style='color:#2F92EE;'>#原发性高草酸尿症#</a>,RNAi疗法的新药很快就会大量问世了, beContent=null, objectType=article, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=63113, encryptionId=135a63113db, topicName=欧盟), TopicDto(id=37137, encryptionId=92f13e13717, topicName=原发性高草酸尿症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:41:26 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1846941, encodeId=15ab18469417a, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Jun 07 08:41:49 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751687, encodeId=8b631e5168768, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Sun Jan 24 00:41:49 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901503, encodeId=8f75901503d7, content=替代移植吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/5A52F5B6BEDC82694F39CB1D2A5D1CF1/100, createdBy=2a7c2136456, createdName=chenwb091, createdTime=Mon Nov 23 17:22:21 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536872, encodeId=44a715368e287, content=<a href='/topic/show?id=7cad1554076' target=_blank style='color:#2F92EE;'>#RNAi疗法Lumasiran#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15540, encryptionId=7cad1554076, topicName=RNAi疗法Lumasiran)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1712732896, createdName=fzwish20004, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590036, encodeId=744e159003607, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900810, encodeId=dec3900810f5, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>lumasiran获得<a href='/topic/show?id=135a63113db' target=_blank style='color:#2F92EE;'>#欧盟#</a>批准治疗1型<a href='/topic/show?id=92f13e13717' target=_blank style='color:#2F92EE;'>#原发性高草酸尿症#</a>,RNAi疗法的新药很快就会大量问世了, beContent=null, objectType=article, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=63113, encryptionId=135a63113db, topicName=欧盟), TopicDto(id=37137, encryptionId=92f13e13717, topicName=原发性高草酸尿症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:41:26 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1846941, encodeId=15ab18469417a, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Jun 07 08:41:49 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1751687, encodeId=8b631e5168768, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Sun Jan 24 00:41:49 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901503, encodeId=8f75901503d7, content=替代移植吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/5A52F5B6BEDC82694F39CB1D2A5D1CF1/100, createdBy=2a7c2136456, createdName=chenwb091, createdTime=Mon Nov 23 17:22:21 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536872, encodeId=44a715368e287, content=<a href='/topic/show?id=7cad1554076' target=_blank style='color:#2F92EE;'>#RNAi疗法Lumasiran#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15540, encryptionId=7cad1554076, topicName=RNAi疗法Lumasiran)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1712732896, createdName=fzwish20004, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590036, encodeId=744e159003607, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sun Nov 22 05:41:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900810, encodeId=dec3900810f5, content=<a href='/topic/show?id=370215539f6' target=_blank style='color:#2F92EE;'>#RNAi疗法#</a>lumasiran获得<a href='/topic/show?id=135a63113db' target=_blank style='color:#2F92EE;'>#欧盟#</a>批准治疗1型<a href='/topic/show?id=92f13e13717' target=_blank style='color:#2F92EE;'>#原发性高草酸尿症#</a>,RNAi疗法的新药很快就会大量问世了, beContent=null, objectType=article, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15539, encryptionId=370215539f6, topicName=RNAi疗法), TopicDto(id=63113, encryptionId=135a63113db, topicName=欧盟), TopicDto(id=37137, encryptionId=92f13e13717, topicName=原发性高草酸尿症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri Nov 20 15:41:26 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
    2020-11-20 lovetcm

    #RNAi疗法#lumasiran获得#欧盟#批准治疗1型#原发性高草酸尿症#,RNAi疗法的新药很快就会大量问世了

    0

相关资讯

ERA-EDTA 2020:RNAi疗法公司Alnylam再发力!Lumasiran治疗1型原发性高草酸尿症III期临床成功

Lumasiran达到ILLUMINATE-A的主要终点,相对于安慰剂而言,草酸尿的平均减少量为53.5%

Alynlam的RNAi药物lumasiran治疗原发性高草酸尿症,完成向欧盟和美国的申请

如果获得批准,lumasiran将成为1型原发性高草酸尿症(PH1)患者的首个治疗药物。

ERA-EDTA 2020:重磅!RNAi疗法Lumasiran治疗高草酸尿症,6个月患者恢复到正常水平

lumasiran治疗组,84%的患者草酸尿排泄达到了正常化或接近正常化的水平,而安慰剂组没有一人实现该目标。

RNAi疗法lumasiran:获得英国MHRA支持治疗1型原发性高草酸尿症

Lumasiran是通过皮下给药、靶向羟基酸氧化酶1(HAO1)的RNAi治疗药物。

FDA为Alnylam的RNAi疗法Lumasiran授予优先审查,用于治疗1型原发性高草酸尿症

Lumasiran是靶向羟基酸氧化酶1(HAO1)、可按季度皮下给药的的RNAi治疗药物。